Browsing Tag
Takeda Pharmaceutical Company Limited
10 posts
Dr. Reddy’s lands Qdenga distribution deal as India prepares first dengue vaccine launch
Dr. Reddy’s Laboratories will promote and distribute Takeda’s Qdenga dengue vaccine in India, creating a new commercial opportunity after regulators approved the country’s first dengue vaccine for people aged four to 60.
Takeda’s MIMRYLO approval unlocks $275m for Protagonist and a $1bn-plus PV bet
Takeda has secured FDA approval for MIMRYLO in adults with polycythemia vera, triggering $275 million of payments to Protagonist Therapeutics and opening a launch Takeda believes could ultimately generate $1 billion to $2 billion in peak global sales.
Takeda’s zasocitinib shows high clearance rates at difficult psoriasis sites
Scalp and palmoplantar clearance rates approached 70% to 77%, but regulatory review, safety labelling and market access will determine the commercial impact.
Takeda is paying Insilico $600m to find drugs before humans take over
Takeda signs a $600 million Insilico AI drug deal. Read how Pharma.AI could reshape pipeline economics, R&D productivity and investor sentiment.
Takeda (NYSE: TAK) boosts psoriasis ambitions as Phase 3 zasocitinib data sharpen oral TYK2 challenge
Takeda’s Phase 3 zasocitinib psoriasis data could reshape the oral TYK2 race. Read what it means for Takeda, rivals, and the market now.
Zasocitinib meets all endpoints in Phase 3 trials, Takeda (NYSE: TAK) eyes FDA submission in 2026
Takeda’s once-daily TYK2 pill hits PASI 100 in Phase 3 psoriasis trials. Find out what this means for rivals, regulators, and Takeda’s pipeline strategy.
How recombinant therapies are reshaping bleeding disorder treatment for children in 2025
Recombinant therapies are replacing plasma-derived treatments for pediatric bleeding disorders—see what’s driving this shift in 2025 and who’s leading.
Vonvendi gets green light for pediatric bleeding disorder care in FDA expansion
Find out how the FDA's expanded approval of Vonvendi opens new treatment avenues for children and adults with all types of von Willebrand disease.
Quebec lists Takeda’s FRUZAQLA for metastatic colorectal cancer under RAMQ formulary
Quebec approves public reimbursement of Takeda’s FRUZAQLA for metastatic colorectal cancer, expanding treatment access in Canada.
Lupin partners with Takeda to launch novel gastrointestinal drug Vonoprazan in India
In a significant development, Lupin Limited, a global pharmaceutical leader, announced a non-exclusive patent licence agreement with Takeda…